NCT06824662View on ClinicalTrials.gov

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

January 1, 2029

Conditions

Glioblastoma WHO Grade IV

Interventions

DRUG

Quisinostat

a highly potent and orally active HDAC inhibitor

Trial Locations (1)

85013

RECRUITING

St. Joseph's Hospital and Medical Center, Phoenix

All Listed Sponsors

lead

Nader Sanai

OTHER